

# Veterinary Teaching Hospital

#### **COLLEGE OF VETERINARY MEDICINE**

## **Funded Study: Treatment of Canine Brain Meningiomas**

University of Illinois Cancer Care Clinic and Comparative Oncology Research Laboratory

**Study Title**: Exploratory study of PAC-1 in combination with hydroxyurea for treatment of canine meningioma

## **Purpose of Study**

The purpose of this study is to investigate the safety and anticancer activities of an investigational combination of chemotherapy agents in dogs with intracranial meningioma. The medication, PAC-1, has been shown to stimulate death selectively in cancer cells which express high levels of procaspase-3, and is believed to synergize with conventional brain tumor therapies inclusive of oral hydroxyurea.

#### **Inclusion Criteria**

- Must have a surgically accessible and measurable primary brain tumor consistent with meningioma on MRI scans.
- The tumor must be measurable (>10mm diameter on post-contrast T1-weighted MR images)
- Must be in overall good health
- No previous chemotherapy or radiation therapy administered
- If applicable, seizures must be well controlled with anti-epileptic medications for at least 6 weeks prior to enrollment

### **Eligibility Diagnostics**

Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed in their dog:

- 1. Brain MRI
- 2. Screening blood work and urinalysis

#### Protoco

Study dogs will receive an investigational combination of chemotherapy (PAC-1 and hydroxyurea) for a treatment period of 28 days. There will be scheduled rechecks for physical and neurological examination along with blood collection. Following the chemotherapy treatment period, a recheck MRI will be performed followed by surgical excision. In the event of complete clinical remission with only oral PAC-1 and hydroxyurea, a continued compassionate use of drug combinations will be considered on a case-by-case basis.

### Compensation

Owners are responsible for eligibility requirements. Once eligibility criteria have been assessed, the study will cover up to \$8,000 worth of costs associated with repeat MRIs, clinical visits during the study period, purchase and dispensing of oral hydroxyurea and PAC-1, and surgery.

## **Contact Information**

Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or <a href="mailto:rmoss81@illinois.edu">rmoss81@illinois.edu</a> to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.